Trena I Mukherjee1, Veena Pillai2, Siti Hafizah Ali2, Frederick L Altice3, Adeeba Kamarulzaman4, Jeffrey A Wickersham5. 1. Yale School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, USA. 2. Centre of Excellence for Research in AIDS (CERiA), Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. 3. Yale School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, USA; Centre of Excellence for Research in AIDS (CERiA), Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Yale University School of Public Health, Division of Epidemiology of Microbial Diseases, CT, USA. 4. Yale School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, USA; Centre of Excellence for Research in AIDS (CERiA), Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. 5. Yale School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, USA; Centre of Excellence for Research in AIDS (CERiA), Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. Electronic address: jeffrey.wickersham@yale.edu.
Abstract
BACKGROUND: Approximately 40%-90% of people who inject drugs (PWID) in Malaysia have hepatitis C (HCV). PWID continue to be disproportionately affected by HCV due to their lack of knowledge, perceived risk and interest in HCV treatment. Education interventions may be an effective strategy for increasing HCV knowledge in PWID, and harm reduction services are uniquely positioned to implement and deploy such interventions. METHODS: We recruited 176 clients from methadone maintenance treatment (MMT: N=110) and needle/syringe programs (NSP: N=66) between November 2015 and August 2016. After baseline knowledge assessments, clients participated in a standardized, 45-min HCV education program and completed post-intervention knowledge assessments to measure change in knowledge and treatment interest. RESULTS: Participants were mostly male (96.3%), Malay (94.9%), and in their early 40s (mean=42.6years). Following the intervention, overall knowledge scores and treatment interest in MMT clients increased by 68% and 16%, respectively (p<0.001). In contrast, NSP clients showed no significant improvement in overall knowledge or treatment interest, and perceived greater treatment barriers. Multivariate linear regression to assess correlates of HCV knowledge post-intervention revealed that optimal dosage of MMT and having had an HIV test in the past year significantly increased HCV knowledge. Having received a hepatitis B vaccine, however, was not associated with increased HCV knowledge after participating in an education session. CONCLUSION: Generally, HCV knowledge and screening is low among clients engaged in MMT and NSP services in Malaysia. Integrating a brief, but comprehensive HCV education session within harm reduction services may be a low-cost and effective strategy in improving overall HCV knowledge and risk behaviors in resource-limited settings. In order to be an effective public health approach, however, education interventions must be paired with strategies that improve social, economic and political outcomes for PWID. Doing so may reduce HCV disparities by increasing screening and treatment interest.
BACKGROUND: Approximately 40%-90% of people who inject drugs (PWID) in Malaysia have hepatitis C (HCV). PWID continue to be disproportionately affected by HCV due to their lack of knowledge, perceived risk and interest in HCV treatment. Education interventions may be an effective strategy for increasing HCV knowledge in PWID, and harm reduction services are uniquely positioned to implement and deploy such interventions. METHODS: We recruited 176 clients from methadone maintenance treatment (MMT: N=110) and needle/syringe programs (NSP: N=66) between November 2015 and August 2016. After baseline knowledge assessments, clients participated in a standardized, 45-min HCV education program and completed post-intervention knowledge assessments to measure change in knowledge and treatment interest. RESULTS:Participants were mostly male (96.3%), Malay (94.9%), and in their early 40s (mean=42.6years). Following the intervention, overall knowledge scores and treatment interest in MMT clients increased by 68% and 16%, respectively (p<0.001). In contrast, NSP clients showed no significant improvement in overall knowledge or treatment interest, and perceived greater treatment barriers. Multivariate linear regression to assess correlates of HCV knowledge post-intervention revealed that optimal dosage of MMT and having had an HIV test in the past year significantly increased HCV knowledge. Having received a hepatitis B vaccine, however, was not associated with increased HCV knowledge after participating in an education session. CONCLUSION: Generally, HCV knowledge and screening is low among clients engaged in MMT and NSP services in Malaysia. Integrating a brief, but comprehensive HCV education session within harm reduction services may be a low-cost and effective strategy in improving overall HCV knowledge and risk behaviors in resource-limited settings. In order to be an effective public health approach, however, education interventions must be paired with strategies that improve social, economic and political outcomes for PWID. Doing so may reduce HCV disparities by increasing screening and treatment interest.
Authors: Louisa Degenhardt; Fiona Charlson; Jeff Stanaway; Sarah Larney; Lily T Alexander; Matthew Hickman; Benjamin Cowie; Wayne D Hall; John Strang; Harvey Whiteford; Theo Vos Journal: Lancet Infect Dis Date: 2016-09-21 Impact factor: 25.071
Authors: Robert Heimer; Scott Clair; Lauretta E Grau; Ricky N Bluthenthal; Patricia A Marshall; Merrill Singer Journal: Addiction Date: 2002-10 Impact factor: 6.526
Authors: Marija Zeremski; Rositsa B Dimova; Roberto Zavala; Steven Kritz; Melissa Lin; Bryce D Smith; Jon E Zibbell; Andrew H Talal Journal: J Addict Med Date: 2014 Jul-Aug Impact factor: 3.702
Authors: N K Martin; G R Foster; J Vilar; S Ryder; M E Cramp; F Gordon; J F Dillon; N Craine; H Busse; A Clements; S J Hutchinson; A Ustianowski; M Ramsay; D J Goldberg; W Irving; V Hope; D De Angelis; M Lyons; P Vickerman; M Hickman Journal: J Viral Hepat Date: 2014-10-07 Impact factor: 3.728
Authors: Eshan U Patel; Sunil S Solomon; Allison M Mcfall; Aylur K Srikrishnan; Amrose Pradeep; Paneerselvam Nandagopal; Oliver Laeyendecker; Aaron A R Tobian; David L Thomas; Mark S Sulkowski; M Suresh Kumar; Shruti H Mehta Journal: Int J Drug Policy Date: 2018-04-19
Authors: Jing Ying Zhang; Zhi Bin Li; Lei Zhang; Jun Wang; Le Ping Huang; Gui Lai Zhan; Zhu Li; Jiang Du; Min Zhao Journal: BMC Infect Dis Date: 2019-09-05 Impact factor: 3.090
Authors: Aida Roziana Ramlan; Nor Ilyani Mohamed Nazar; Afidalina Tumian; Norny Syafinaz Ab Rahman; Dzawani Mohamad; Mat Sharil Abdul Talib; Khairul Faizan M Zakaria; Muhammad Azzim Izuddin; Nadia Akmal Zainal Abidin; Syarifah Syafiqah T Syed Manso; Wan Nur Khairiyah Wan Hassan Journal: J Pharm Bioallied Sci Date: 2020-11-05
Authors: Semvua B Kilonzo; Daniel W Gunda; David C Majinge; Hyasinta Jaka; Paulina M Manyiri; Fredrick Kalokola; Grahame Mtui; Elichilia R Shao; Fatma A Bakshi; Alex Stephano Journal: BMC Infect Dis Date: 2021-07-21 Impact factor: 3.090